Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to...
292 insider purchases on record · latest filing 2026-03-06.
Insiders have also filed 13 sale transactions at DCTH.